Why carry out this study?

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have emerged as pivotal therapies for patients with type 2 diabetes mellitus (T2DM). Several large-scale randomized clinical trials, such as the EMPA-REG OUTCOME and DAPA-HF, have demonstrated a considerable reduction in major adverse cardiovascular events (MACE)

Several putative mechanisms to explain these cardioprotective effects have been proffered but not yet formally proven nor refuted. To our knowledge, the question of whether SGLT2 inhibition also resulted in pleiotropic antiplatelet effects remained unanswered

What was learned from the study?

Empagliflozin achieved a greater antiplatelet effect and led to significantly lower platelet reactivity than in Trinidadian patients with CAD and T2DM without empagliflozin. This mechanistic pilot study can be clinically relevant because of an improved efficacy and safety profile